title: Respiratory metapneumoviral infection without co-infection in association with acute and chronic lung allograft dysfunction.
abstract: BACKGROUND
  Metapneumoviral respiratory infection is a community-acquired respiratory viral (CARV) infection. Lung transplantation recipients exposed to CARV are at risk for development of allograft rejection. The cellular and molecular pathways initiated by viral infection leading to allograft dysfunction are not completely understood. The aim of this study was to identify human metapneumoviral (hMPV) cases in association with allograft rejection.
  
  
  METHODS
  A literature search was conducted to identify cases of both hMPV and allograft rejection within 6 months of the initial infection. This resulted in 1,007 lung transplantation recipients, with a total of 2,883 samples identified. Of these, 57 demonstrated isolated hMPV without co-infection with other agents.
  
  
  RESULTS
  The results of the study indicate that 35% of acute hMPV infections without co-infection, at the time of detection by molecular diagnostic platforms, were associated with acute cellular rejection within 3 months. There were 9.4% of the cases subsequently associated with chronic allograft dysfunction/bronchiolitis obliterans syndrome, which was collectively termed chronic rejection for purposes of analysis. In conclusion, the prompt identification of isolated hMPV from lung transplantation patients is an important treatable risk factor for subsequent allograft dysfunction. The cellular and molecular pathogenesis of viral-induced allograft rejection remains a topic of future study.
authors.affiliation: Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA.
authors.forename: Amrita
authors.initials: A
authors.lastname: Dosanjh
keywords: acute cellular rejection; allograft; bronchiolitis obliterans; lung; metapneumovirus; viral infection
references.citation: Am J Transplant. 2005 Aug;5(8):2031-6
references.pmid: 15996256
references.citation: J Med Virol. 2006 Mar;78(3):408-16
references.pmid: 16419110
references.citation: J Infect Dis. 2005 Sep 15;192(6):1052-60
references.pmid: 16107959
references.citation: Transpl Infect Dis. 2011 Jun;13(3):324-8
references.pmid: 21631655
references.citation: Antivir Ther. 2007;12(4 Pt B):627-38
references.pmid: 17944270
references.citation: J Clin Microbiol. 2007 Feb;45(2):548-52
references.pmid: 17065270
references.citation: J Heart Lung Transplant. 2007 Aug;26(8):862-4
references.pmid: 17692793
references.citation: Transpl Infect Dis. 2010 Aug 1;12(4):330-5
references.pmid: 20456714
references.citation: J Heart Lung Transplant. 2005 Nov;24(11):1891-901
references.pmid: 16297797
references.citation: Clin Transplant. 2013 Jan-Feb;27(1):E64-71
references.pmid: 23278569
references.citation: Transplantation. 2009 May 27;87(10):1530-7
references.pmid: 19461490
references.citation: J Clin Virol. 2014 Mar;59(3):141-7
references.pmid: 24480724
references.citation: Epidemiol Infect. 2013 Oct;141(10):2213-23
references.pmid: 23290557
references.citation: Transplantation. 2010 Apr 27;89(8):1028-33
references.pmid: 20075787
references.citation: Am J Respir Crit Care Med. 2008 Oct 15;178(8):876-81
references.pmid: 18658110
references.citation: Clin Infect Dis. 2010 Jul 15;51(2):163-70
references.pmid: 20524853
references.citation: Semin Respir Crit Care Med. 2011 Aug;32(4):471-93
references.pmid: 21858751